Mavacamten and the enzyme CYP2C19
Mavacamten is processed within the body primarily by the enzyme CYP2C19 and to a lesser extent by CYP3A4. The activity of the CYP2C19 enzyme can vary considerably depending on your genetic predisposition, which means the efficacy of mavacamten and the risk of side effects can also differ from person to person.
Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with mavacamten.
Read more about CYP2C19 enzyme »